User Name:     Password:        Join Us
  • 1
  • 2
  • 3
  • 4
▪ China is to award whistleblowers heavily – foreign companies are more vulnerable t
▪ 130 Chinese headhunters arrested, involving breach of 200 million pieces of person
▪ Corporate Compliance Programs Evaluation Issued by US DOJ (Chinese Translation)
▪ The prospect is promising to commercialize Level-3 autonomous driving in China
▪ Intelligent and digital infrastructures are scheduled to accompany automatic vehic
▪ Will China illegalize VIEs?
▪ You cannot miss the gold rush under China's new Foreign Investment Law
▪ Data must stay in China to get classified protection under Cyber Security Law
▪ China is to fast-track law-making in autonomous driving
▪ What compliance obligations to meet to transfer data from within China?
▪ Chinese government uses digital forensics technology to dig bribery evidence
▪ A Chinese medical device distributor fined CNY 50,000 for bribing with Moutai
▪ How would Chinese E-commerce Law affect you (1)?
▪ Conflict between the culture and the Party’s rules: $70 gift money got a director
▪ "Excessive Pricing" from perspective of Competition Law
▪ Does China prohibit cross-border transfer of scientific data?
▪ Hypermarket Caesar jailed for ten years for giving “reward for go-between”
▪ How is environmental protection tax collected in China?
▪ China Redefined Bribery Anticompetitive in Nature
▪ China is to amend its Constitution
▪ Chinese government vowed to crack down on bribe givers more harshly
▪ China has its own Dodd-Frank; the award for whistleblower could be US$ 80K
▪ Chinese government may LIUZHI a suspect of wrongdoing
▪ Cooking clinical trial data is rampant and now criminally punishable in China
▪ 5th Viadrina Compliance Congress
▪ Does a compliance bird eat nothing?
▪ How Are Drugs Being Sold in China Despite the Anti-Corruption Crusading
▪ Chinese whistle-blower lauded while French boss fled out of China
▪ Life Sentence for Deputy Chief Justice of China
▪ Why Is Chinese Anti-bribery Law a Very Important Compliance Obligation?
▪ The Report on Corporate Compliance Management in China (2016)
▪ Use of "predictive coding" in eDiscovery document review…best friend or job replac
▪ Civil Fraud v. Criminal Fraud: Criminal Proceedings Not a Silver Bullet to Resolve
▪ Corrupt Chinese drug administrators jailed or executed, whose family members ended
▪ Tone from the middle cannot be ignored
▪ Is bribing a Chinese doctor bribing an FCPA governmental official?
▪ Criminal and Administrative Liability under China's Competition Laws
▪ Model Standards for Trade Association Compliance with China's AML
▪ Double Exposure to Legal Risk Under China's Competition Laws: Comments Upon the Ex
▪ New Privacy Standards for New Data
▪ Chinese Police Are Foxhunting Corrupt Officials
▪ Transfer of Personal Data Overseas from Singapore: Recent Enhanced Provisions
▪ New Guidance on Antitrust Notifications in China
▪ China Issued the Standards on the Quality Management of Using Medical Devices (Dra
▪ China Imposes Harsher Liabilities for Environmental Non-Compliance
▪ GSK Faces Two Corruption Fights in East and West
▪ European Court of Justice Abrogates Data Retention and Allows Data Detention
▪ China Is to Adopt Risk-based Supervisory Rules on Medical Devices
▪ China to Set Food & Drug Police
▪ Don't Put All Medical Eggs into One Blacklisted Basket
 
Home > Anti-Bribery & Fraud
GSK Faces Two Corruption Fights in East and West

News from China


 

On May 14, 2014, Xinhua News Agency reported that Chinese police have concluded a 10-month investigation against GlaxoSmithKline (GSK) and uncovered evidence of “large-scale” bribery in Chinese hospitals and other medical institutions, with illegal income amounting to “billions of Chinese yuan.”  


Investigators have delivered their findings to Chinese prosecutors, who have begun reviewing the case, the news agency reported, citing unnamed sources with the Hunan police authority.  It is also reported that Changsha People’s Procurator has indicted a total of 35 defendants in the GlaxoSmithKline (GSK) commercial bribery case, including GSK’s China unit.  The 35 defendants include corporate entities such as GSK’s China unit, pharmaceutical distributors and a Chinese travel agency. They also include individuals such as Mark Reilly, the former head of GSK China, other former GSK China managers, employees of the implicated travel agency and pharmaceutical distributors.


According to the Xinhua report, the police have focused on three allegations: the crime of bribing of non-government working personnel, the crime of a unit making bribes and the crime of making bribes to a unit.  It is disclosed that GSK’s China management had even bribed officials at AICs in Beijing and Shanghai in an attempt to quash their anti-corruption investigations.


News from UK


GlaxoSmithKline PLC is now the subject of an investigation by the United Kingdom's Serious Fraud Office, the company announced in a statement on May 27, 2014.


 

The British pharmaceutical giant provided no specific details on the nature of the investigation, but reassured investors and the public that it was doing everything in its power to assist authorities in gathering information.


 

“GSK is committed to operating its business to the highest ethical standards and will continue to cooperate fully with the SFO,” the statement said.


 

According to its website, the U.K. Serious Fraud Office investigates and prosecutes “those who commit serious or complex fraud, bribery and corruption and pursuing them and others for the proceeds of their crime.”

 

It is clear that GSK will have to fight at two frontiers simultaneously. 

 

 

 

 

Tweet Like Email LinkedIn
There are no comments for this journal entry. To create a new comment, use the form below.
    Enter your information below to add a new comment.
Author:   
Email:    (optional)
URL:    (optional)
Content:  
Code: *
    
  Comment Moderation Enabled
Your comment will not appear until it has been cleared by a website editor.
The Compliance Reviews COPYRIGHT © 2013-19 All Rights Reserved. Supported by International Risk and Compliance Association and International Risk and Compliance Institute Limited. 沪ICP备10034943号-8

31010502002477